ELEM Biotech is pleased to announce the successful completion of our Series B funding round, raising $25 million to support our mission of advancing drug discovery through high-throughput gene editing technologies.
Investment Highlights
The funding round was led by prominent life sciences investors including:
- BioVentures Capital (Lead Investor)
- Genomics Innovation Fund
- Strategic pharmaceutical industry partners
This brings our total funding to $40 million since founding in 2020.
Strategic Priorities
The Series B proceeds will support three key initiatives:
1. Platform Expansion
- Increase monthly production capacity to 5,000+ knockout cell pools
- Implement automated liquid handling and quality control systems
- Develop next-generation editing technologies (base editing, prime editing)
- Expand cell line portfolio to include primary cells and organoid models
2. Facility Enhancement
- Construct new 15,000 sq ft BSL-2 production facility
- Install state-of-the-art cell culture and analytical equipment
- Implement comprehensive environmental monitoring systems
- Achieve ISO 9001 certification for quality management
3. Service Innovation
- Launch custom CRISPR library design services
- Develop integrated screening and hit validation workflows
- Establish strategic partnerships with CRO and pharmaceutical companies
- Expand technical support and customer success teams
Market Opportunity
The global gene editing market is projected to reach $12 billion by 2027, driven by:
- Increasing adoption in drug discovery and development
- Growing investment in precision medicine
- Declining costs of genome editing technologies
- Regulatory acceptance of gene-edited therapeutic products
Leadership Perspective
"This funding validates our technology platform and business model," said Dr. James Liu, CEO and Co-founder of ELEM Biotech. "We're seeing strong demand from pharmaceutical and biotech companies seeking high-quality, scalable gene editing solutions. This investment enables us to meet that demand while continuing to innovate."
Looking Ahead
Over the next 18 months, we plan to:
- Double our team size, with emphasis on R&D and technical support
- Launch at least three new product lines
- Establish collaborations with 10+ pharmaceutical companies
- Publish validation data in peer-reviewed journals
About ELEM Biotech
Founded in 2020, ELEM Biotech specializes in high-throughput gene editing for drug discovery and functional genomics research. Our platform combines CRISPR technology with rigorous quality control to deliver validated knockout cell pools, stable cell lines, and custom gene editing services.